N@N

Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November

^{Published on 2012-11-09 18:01:25 - Market Wire}
 

Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November -- DUBLIN, Nov. 9, 2012 /PRNewswire/ --

DUBLIN, Nov. 9, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: [ JAZZ ]) announced today that the company will participate in three upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at [ www.jazzpharmaceuticals.com ]. The conferences and presentation times include:

• Lazard Capital Markets 9^th Annual Healthcare Conference in New York, NY on Wednesday, November 14, 2012 at 8:00 a.m. EST/1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide a business update;                                                         
• Credit Suisse 2012 Healthcare Conference in Phoenix, AZ on Thursday, November 15, 2012 at 8:30 a.m. MST/10:30 a.m. EST/3:30 p.m. GMT. Bruce Cozadd will provide a business update;                                                                                                                       
• Piper Jaffray 24th Annual Healthcare Conference in New York, NY on Wednesday, November 28, 2012 at 10:00 a.m. EST/3:00 p.m. GMT. Kate Falberg, executive vice president and chief financial officer, will provide a business update.

An archived version of each webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at [ www.jazzpharmaceuticals.com ].

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem^® (sodium oxybate) oral solution, Erwinaze^® (asparaginase Erwinia chrysanthemi), Prialt^® (ziconotide) intrathecal infusion, Luvox CR^® (fluvoxamine maleate), FazaClo^® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma.

SOURCE Jazz Pharmaceuticals plc